Annual Cash & Cash Equivalents
$22.59 M
-$9.56 M-29.74%
December 31, 2023
Summary
- As of February 7, 2025, LSTA annual cash & cash equivalents is $22.59 million, with the most recent change of -$9.56 million (-29.74%) on December 31, 2023.
- During the last 3 years, LSTA annual cash & cash equivalents has risen by +$6.08 million (+36.83%).
- LSTA annual cash & cash equivalents is now -51.03% below its all-time high of $46.13 million, reached on December 1, 2013.
Performance
LSTA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$19.51 M
-$8.78 M-31.05%
September 30, 2024
Summary
- As of February 7, 2025, LSTA quarterly cash and cash equivalents is $19.51 million, with the most recent change of -$8.78 million (-31.05%) on September 30, 2024.
- Over the past year, LSTA quarterly cash and cash equivalents has dropped by -$3.08 million (-13.65%).
- LSTA quarterly cash and cash equivalents is now -57.71% below its all-time high of $46.13 million, reached on December 1, 2013.
Performance
LSTA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
LSTA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -29.7% | -13.7% |
| 3 y3 years | +36.8% | -13.7% |
| 5 y5 years | +119.4% | -13.7% |
LSTA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -29.7% | at low | -41.5% | +53.0% |
| 5 y | 5-year | -29.7% | +61.0% | -41.5% | +53.0% |
| alltime | all time | -51.0% | >+9999.0% | -57.7% | >+9999.0% |
Lisata Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $19.51 M(-31.0%) |
| Jun 2024 | - | $28.29 M(+29.8%) |
| Mar 2024 | - | $21.80 M(-3.5%) |
| Dec 2023 | $22.59 M(-29.7%) | $22.59 M(-30.3%) |
| Sep 2023 | - | $32.43 M(+36.9%) |
| Jun 2023 | - | $23.69 M(-15.9%) |
| Mar 2023 | - | $28.16 M(-12.4%) |
| Dec 2022 | $32.15 M(+30.5%) | $32.15 M(+2.1%) |
| Sep 2022 | - | $31.48 M(-5.6%) |
| Jun 2022 | - | $33.35 M(+161.6%) |
| Mar 2022 | - | $12.75 M(-48.3%) |
| Dec 2021 | $24.65 M(+49.3%) | - |
| Dec 2021 | - | $24.65 M(+93.0%) |
| Sep 2021 | - | $12.77 M(-1.3%) |
| Jun 2021 | - | $12.94 M(-55.0%) |
| Mar 2021 | - | $28.74 M(+74.1%) |
| Dec 2020 | $16.51 M(+17.7%) | $16.51 M(-22.0%) |
| Sep 2020 | - | $21.16 M(-20.7%) |
| Jun 2020 | - | $26.68 M(+28.6%) |
| Mar 2020 | - | $20.75 M(+47.8%) |
| Dec 2019 | $14.03 M(+36.2%) | $14.03 M(+10.7%) |
| Sep 2019 | - | $12.67 M(+7.8%) |
| Jun 2019 | - | $11.75 M(-18.5%) |
| Mar 2019 | - | $14.42 M(+40.1%) |
| Dec 2018 | $10.30 M(-64.7%) | $10.30 M(-28.4%) |
| Sep 2018 | - | $14.37 M(-36.7%) |
| Jun 2018 | - | $22.73 M(+5.2%) |
| Mar 2018 | - | $21.60 M(-25.9%) |
| Dec 2017 | $29.16 M(+312.1%) | $29.16 M(+93.4%) |
| Sep 2017 | - | $15.08 M(-34.6%) |
| Jun 2017 | - | $23.04 M(+92.1%) |
| Mar 2017 | - | $12.00 M(+69.5%) |
| Dec 2016 | $7.08 M(-65.2%) | $7.08 M(-62.0%) |
| Sep 2016 | - | $18.61 M(+5.1%) |
| Jun 2016 | - | $17.70 M(-30.4%) |
| Mar 2016 | - | $25.43 M(+25.1%) |
| Dec 2015 | $20.32 M(+6.0%) | $20.32 M(-15.5%) |
| Sep 2015 | - | $24.04 M(-33.6%) |
| Jun 2015 | - | $36.21 M(+89.3%) |
| Mar 2015 | - | $19.13 M(-0.2%) |
| Dec 2014 | $19.17 M(-58.4%) | $19.17 M(-40.3%) |
| Sep 2014 | - | $32.14 M(-2.2%) |
| Jun 2014 | - | $32.87 M(-20.5%) |
| Mar 2014 | - | $41.36 M(-10.3%) |
| Dec 2013 | $46.13 M(+235.8%) | $46.13 M(+172.2%) |
| Sep 2013 | - | $16.95 M(+15.1%) |
| Jun 2013 | - | $14.72 M(+59.1%) |
| Mar 2013 | - | $9.25 M(-32.6%) |
| Dec 2012 | $13.74 M(+249.1%) | $13.74 M(+154.8%) |
| Sep 2012 | - | $5.39 M(+155.2%) |
| Jun 2012 | - | $2.11 M(-90.3%) |
| Mar 2012 | - | $21.77 M(+453.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2011 | $3.94 M(-74.8%) | $3.94 M(-66.4%) |
| Sep 2011 | - | $11.71 M(+141.5%) |
| Jun 2011 | - | $4.85 M(-48.5%) |
| Mar 2011 | - | $9.41 M(-39.7%) |
| Dec 2010 | $15.61 M(+118.1%) | $15.61 M(+283.9%) |
| Sep 2010 | - | $4.07 M(-62.9%) |
| Jun 2010 | - | $10.96 M(-4.0%) |
| Mar 2010 | - | $11.42 M(+59.5%) |
| Dec 2009 | $7.16 M(+1561.9%) | $7.16 M(+22.4%) |
| Sep 2009 | - | $5.85 M(-44.0%) |
| Jun 2009 | - | $10.45 M(+2560.3%) |
| Mar 2009 | - | $392.80 K(-8.8%) |
| Dec 2008 | $430.80 K(-81.3%) | $430.80 K(-45.8%) |
| Sep 2008 | - | $794.40 K(+50.1%) |
| Jun 2008 | - | $529.10 K(-45.4%) |
| Mar 2008 | - | $969.80 K(-57.9%) |
| Dec 2007 | $2.30 M(+427.6%) | $2.30 M(-36.9%) |
| Sep 2007 | - | $3.65 M(+4172.6%) |
| Jun 2007 | - | $85.40 K(-91.9%) |
| Mar 2007 | - | $1.06 M(+142.5%) |
| Dec 2006 | $436.70 K(-10.7%) | $436.70 K(-66.9%) |
| Sep 2006 | - | $1.32 M(+44.7%) |
| Jun 2006 | - | $912.30 K(+3035.1%) |
| Mar 2006 | - | $29.10 K(-94.0%) |
| Dec 2005 | $488.90 K(+1652.3%) | $488.90 K(+4601.0%) |
| Sep 2005 | - | $10.40 K(+3366.7%) |
| Jun 2005 | - | $300.00(-94.4%) |
| Mar 2005 | - | $5400.00(-80.6%) |
| Dec 2004 | $27.90 K(-86.8%) | $27.90 K(-94.0%) |
| Sep 2004 | - | $461.40 K(>+9900.0%) |
| Jun 2004 | - | $1800.00(-92.4%) |
| Mar 2004 | - | $23.60 K(-88.8%) |
| Dec 2003 | $210.90 K(+992.7%) | $210.90 K(+546.9%) |
| Sep 2003 | - | $32.60 K(+18.5%) |
| Jun 2003 | - | $27.50 K(+84.6%) |
| Mar 2003 | - | $14.90 K(-22.8%) |
| Dec 2002 | $19.30 K(-62.4%) | $19.30 K(-61.4%) |
| Sep 2002 | - | $50.00 K(+474.7%) |
| Jun 2002 | - | $8700.00(-79.3%) |
| Mar 2002 | - | $42.00 K(-18.1%) |
| Dec 2001 | $51.30 K(-40.1%) | $51.30 K(-58.6%) |
| Sep 2001 | - | $123.90 K(+64.5%) |
| Jun 2001 | - | $75.30 K(+65.1%) |
| Mar 2001 | - | $45.60 K(-46.7%) |
| Dec 2000 | $85.60 K(-94.8%) | $85.60 K(-92.5%) |
| Sep 2000 | - | $1.14 M(+5.8%) |
| Jun 2000 | - | $1.08 M(-29.1%) |
| Mar 2000 | - | $1.53 M |
| Dec 1999 | $1.64 M(+694.7%) | - |
| Dec 1998 | $206.30 K(-81.7%) | - |
| Mar 1998 | $1.13 M(+8453.8%) | - |
| Mar 1997 | $13.20 K(>+9900.0%) | - |
| Mar 1996 | $100.00 | - |
FAQ
- What is Lisata Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Lisata Therapeutics?
- What is Lisata Therapeutics annual cash & cash equivalents year-on-year change?
- What is Lisata Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Lisata Therapeutics?
- What is Lisata Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Lisata Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of LSTA is $22.59 M
What is the all time high annual cash & cash equivalents for Lisata Therapeutics?
Lisata Therapeutics all-time high annual cash & cash equivalents is $46.13 M
What is Lisata Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, LSTA annual cash & cash equivalents has changed by -$9.56 M (-29.74%)
What is Lisata Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of LSTA is $19.51 M
What is the all time high quarterly cash and cash equivalents for Lisata Therapeutics?
Lisata Therapeutics all-time high quarterly cash and cash equivalents is $46.13 M
What is Lisata Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, LSTA quarterly cash and cash equivalents has changed by -$3.08 M (-13.65%)